Sunday, July 5, 2015

Underwriters exercise Dipexium over-allotment option

Underwriters exercise Dipexium over-allotment option

July 1, 2015 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals (NASDAQ:DPRX) has closed a public offering of 1,480,000 common shares and underwriters also exercised their over-allotment option in full to purchase an additional 222,000 shares of common stock. Net proceeds of approximately $19.7-million will be used to fund operations and for other general corporate purposes, including, but not limited to, internal R&D […]

HCW starts Novogen at buy

HCW starts Novogen at buy

July 1, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of Novogen (NASDAQ:NVGN) with a “buy” rating and $8.50 price target. The stock closed at $4.02 on Tuesday. Novogen of Australia is developing novel therapies against cancer stem cells. The company has developed two drug families, super-benzopyrans (SBPs) and anti-tropomyosins (ATMs), for the treatment of solid tumors. An ATM, […]

ViewRay secures up to $50-million from CRG

ViewRay secures up to $50-million from CRG

June 30, 2015 by · Leave a Comment 

Tweet Closely-held ViewRay, makers of MRIdian, the world’s first and only clinical MRI-guided radiation therapy system, has secured up to $50-million in debt financing from CRG (formerly Capital Royalty L.P.), a healthcare investment firm. Through the transaction with CRG, ViewRay will initially access $30-million of debt, which is interest only for three years, enabling the […]

BioLight obtains CE Mark for CellDetect test

BioLight obtains CE Mark for CellDetect test

June 30, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments’ (OTC:BLGTY; TASE:BOLT) CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories. In addition, the European Patent Office has issued a patent related to the core of the CellDetect technology. The patent will be […]

Analysts start EndoChoice at outperform, buy

Analysts start EndoChoice at outperform, buy

June 30, 2015 by · Leave a Comment 

Tweet William Blair and Stifel initiated coverage of EndoChoice Holdings (NYSE:GI) with “outperform” and “buy” ratings, respectively. EndoChoice’s comprehensive portfolio of single-use GI endoscopy products and pathology/endoscopy services offers GI specialists (gastroenterologists) a unique, “one-stop shop” for all endoscopy procedure requirements, writes Stifel analyst Rick Wise, who set a price target of $20 on the […]

BiondVax posts positive interim universal vaccine data

BiondVax posts positive interim universal vaccine data

June 29, 2015 by · Leave a Comment 

Tweet BiondVax Pharmaceuticals (NASDAQ, TASE:BVXV) has reported positive preliminary results from the BVX-006 Phase 2 clinical trial of M-001, its candidate for a universal influenza vaccine. In the trial, M-001 was injected intramuscularly to volunteers between the ages of 50-to-65, followed by an administration of the 2014/15-season trivalent influenza vaccine three weeks later. M-001 was […]

Cynapsus enrols first patient in Phase 3 trial

Cynapsus enrols first patient in Phase 3 trial

June 29, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (NASDAQ:CYNA; TSX:CTH) has enrolled the first patient in the CTH-300 clinical trial, a Phase 3 study to examine the efficacy, safety and tolerability of APL-130277 for the acute treatment of “off”episodes in patients with Parkinson’s disease (PD). The CTH-300 trial is a double-blind, placebo-controlled, parallel-design study with an estimated enrollment of 126 […]

Dipexium prices $18.5-million common stock offering

Dipexium prices $18.5-million common stock offering

June 25, 2015 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals (NASDAQ:DPRX) has priced an underwriting of 1,480,000 common shares at a price of $12.50 each for gross proceeds of $18.5-million. The offering is expected to close on June 30. Dipexium has granted the underwriters a 30-day option to purchase up to an additional 222,000 shares of to cover over-allotments, if any. Raymond […]

Cynapsus’ drug shown to improve Parkinson’s symptoms

Cynapsus’ drug shown to improve Parkinson’s symptoms

June 25, 2015 by · Leave a Comment 

Tweet Cynapsus Therapeutics (NASDAQ:CYNA; TSX:CTH) has presented data from clinical trials of APL-130277, a sublingual apomorphine thin film under development for the on-demand treatment of off episodes associated with Parkinson’s disease (PD). Data from the company’s CTH-105, CTH-104 and CTH-103 clinical studies, presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS) […]

Ciclofilin demonstrates anti-fibrotic activity with CPI-431-32

Ciclofilin demonstrates anti-fibrotic activity with CPI-431-32

June 24, 2015 by · Leave a Comment 

Tweet Closely-held Ciclofilin Pharmaceuticals’ lead antiviral drug has demonstrated anti-fibrotic activity in a liver fibrosis animal model. CPI-431-32 is a proprietary cyclophilin antagonist that potently inhibits hepatitis B virus (HBV). It acts primarily by inhibiting HBV’s ability to hijack and utilize the host cell protein, cyclophilin, to propagate infection. In vitro experiments conducted in collaboration […]

Next Page »

Email Newsletters with Constant Contact
Google+